Chimerin 2
Yuan S, Miller DW, Barnett GH, et al. (1995), “Identification and characterization of human beta 2-chimaerin: association with malignant transformation in astrocytoma”, Cancer Res. 55 (15): 3456–61, PMID 7614486
Caloca MJ, Fernandez N, Lewin NE, et al. (1997), “Beta2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters”, J. Biol. Chem. 272 (42): 26488–96, doi:10.1074/jbc.272.42.26488, PMID 9334226
Caloca MJ, Garcia-Bermejo ML, Blumberg PM, et al. (1999), “beta2-chimaerin is a novel target for diacylglycerol: binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain”, Proc. Natl. Acad. Sci. U.S.A. 96 (21): 11854–9, doi:10.1073/pnas.96.21.
Gerhard DS, Wagner L, Feingold EA, et al. (2004), “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)”, Genome Res. 14 (10B): 2121–7, doi:10.1101/gr.2596504, PMC 528928, PMID 15489334, http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=528928
Canagarajah B, Leskow FC, Ho JY, et al. (2004), “Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin”, Cell 119 (3): 407–18, doi:10.1016/j.cell.2004.10.012, PMID 15507211
Hashimoto R, Yoshida M, Kunugi H, et al. (2005), “A missense polymorphism (H204R) of a Rho GTPase-activating protein, the chimerin 2 gene, is associated with schizophrenia in men”, Schizophrenia Research 73 (2–3): 383–5, doi:10.